BioCentury
ARTICLE | Financial News

Audentes raises $65 million in series C

October 14, 2015 1:32 AM UTC

Gene therapy company Audentes Therapeutics Inc. (San Francisco, Calif.) raised $65 million in a series C round co-led by existing investor Sofinnova Ventures and new investor Redmile Group. New investors RA Capital; T. Rowe Price; Rock Springs Capital; Cormorant Asset Management; Cowen Private Investments; and Foresite Capital also participated, as did existing investors OrbiMed; 5AM Ventures; Versant Ventures; Deerfield Management; and Venrock.

Audentes develops gene therapies to treat rare diseases. Its preclinical candidates include AT001, an adeno-associated viral serotype 8 (AAV8) vector delivering the myotubularin 1 ( MTM1) gene to treat X-linked myotubular myopathy; and AT002, an AAV9 vector carrying the acid alpha glucosidase ( GAA) gene to treat Pompe's disease. ...